Bristol-Myers Squibb (BMY) Posts Quarterly Results
Bristol-Myers Squibb (NYSE:BMY) announced its earnings results on Tuesday. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.03, Analyst Ratings News reports. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.89 billion.
Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 50.36 on Tuesday. Bristol-Myers Squibb has a one year low of $39.18 and a one year high of $57.49. The stock’s 50-day moving average is $51.63 and its 200-day moving average is $52.06. The company has a market cap of $83.106 billion and a price-to-earnings ratio of 32.79.
Several analysts have recently commented on the stock. Analysts at Ned Davis Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. On the ratings front, analysts at Zacks reiterated a “neutral” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, March 19th. They now have a $57.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb to $48.00 in a research note on Wednesday, March 19th. They now have a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $56.77.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.